<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392808</url>
  </required_header>
  <id_info>
    <org_study_id>CSISP-VAC-MENC1</org_study_id>
    <secondary_id>EUDRA 2006-003525-82</secondary_id>
    <nct_id>NCT00392808</nct_id>
  </id_info>
  <brief_title>Immunogenicity of the Booster Dose of Two MenC Vaccines</brief_title>
  <acronym>CSISP-MENC1</acronym>
  <official_title>Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Superior de Investigación en Salud Publica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Superior de Investigación en Salud Publica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the immune response of toddlers, to a booster dose in
      the second year of life of two meningococcal C conjugated polysaccharide vaccine, and to
      assess the interchangeability of the two different vaccines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children 14 to 18 months of life, previously vaccinated with 2 doses of tetanus toxoid
      conjugated polysaccharide men C vaccine or three doses of the CRM197 conjugated
      polysaccharide men C vaccine before 7 months of age, are randomized to receive any of the two
      vaccines. Serum antibody activity against meningococcus C will be measured inmediately before
      and 4 weeks after the booster dose. Children will also be vaccinated with a combined vaccine
      containing DTaP+IPV+Hib.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Bactericidal Activity Against MenC</measure>
    <time_frame>One month after booster dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Antibody Titers Against Haemophilus Influenzae Type b.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">389</enrollment>
  <condition>Meningococcal Infection</condition>
  <arm_group>
    <arm_group_label>MENC-CRM/MENC-CRM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children primed with 3 doses of MenC-CRM vaccine, Intervention: boosted with one dose of MenC-CRM vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MENC-CRM/MENC-TT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children Primed with three doses of MenC-CRM vaccine. Intervention: boosted with one dose of MenC-TT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MENC-TT/MENC-CRM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children primovacccinated with two MenC-TT vaccine doses. Intervention: boosted with one dose MenC-CRM vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MENC-TT/MENC-TT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children primovacccinated with two MenC-TT vaccine doses. Intervention boosted with one dose MenC-TT vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>conjugated polysaccharide menC vaccine</intervention_name>
    <description>Booster vaccine dose at 14 to 18 months.</description>
    <arm_group_label>MENC-CRM/MENC-CRM</arm_group_label>
    <arm_group_label>MENC-CRM/MENC-TT</arm_group_label>
    <arm_group_label>MENC-TT/MENC-CRM</arm_group_label>
    <arm_group_label>MENC-TT/MENC-TT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy toddlers of both sexes

          -  Toddlers of 14 to 19 months of age (including the day that the toddler is 14 and the
             day before he is 19 months of age)

          -  Children previously vaccinated with two doses of polysaccharide meningococcal C
             vaccine conjugated to tetanus toxoid or three doses of polysaccharide meningococcal C
             conjugated to CRM197 before 7 month of age.

          -  Informed consent signed by one or both parents who are adequately informed about the
             study.

        Exclusion Criteria:

          -  Toddlers with severe diseases or axilar temperature ≥ 38,0ºC at inclusion time

          -  Toddlers with severe chronic diseases

          -  Toddlers who have received any other vaccine within the last month or with a
             programmed vaccination within the 28 subsequent days after the administration of the
             vaccine of study.

          -  Toddlers with clinical or bacteriological diagnosis of previous meningococcal disease.

          -  Toddlers with hypersensitivity to any of the components of the vaccines to study or
             antibiotics used during the manufacturing process that could be present as non-
             detectable traces (streptomycin, neomycin, polymyxin B).

          -  Toddlers with personal history of convulsions.

          -  Toddlers with known bleeding disorder no controlled

          -  Toddlers with known congenital or acquired immunodeficiency

          -  Toddlers who are receiving or have been received any treatment that could change the
             immune response (administration of intravenous immunoglobulin, systemic
             corticosteroids or haemoderivates) within the 3 previous months.

          -  A toddler that under investigator opinion is probable to be lost during the follow-up

          -  A toddler that is currently included or is planned to be included in any other
             clinical trial.

          -  A toddler that under investigator opinion must not be included in the study due to
             other medical or social reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Months</minimum_age>
    <maximum_age>19 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Diez-Domingo, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centro Superior Investigacion Salud Publica (CSISP)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad Rey Juan Carlos I</name>
      <address>
        <city>Madrid</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Superior Investigación en Salud Publica</name>
      <address>
        <city>Valencia</city>
        <zip>46020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Diez-Domingo J, Planelles-Cantarino MV, Baldo-Torrenti JM, Ubeda-Sansano I, Jubert-Rosich A, Puig-Barbera J, Gutierrez-Gimeno MV. Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life. Pediatr Infect Dis J. 2010 Aug;29(8):768-70. doi: 10.1097/INF.0b013e3181d9e653.</citation>
    <PMID>20375851</PMID>
  </results_reference>
  <results_reference>
    <citation>Díez-Domingo J, Cantarino MV, Torrentí JM, Sansano MI, Rosich AJ, Merino AH, de Miguel AG, González JB, Marcos MD; MenC Study Group. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J. 2010 Feb;29(2):148-52. doi: 10.1097/INF.0b013e3181b9a831.</citation>
    <PMID>19927040</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <results_first_submitted>August 6, 2013</results_first_submitted>
  <results_first_submitted_qc>August 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 11, 2013</results_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal vaccine</keyword>
  <keyword>Immunization, secondary</keyword>
  <keyword>vaccines conjugated</keyword>
  <keyword>Meningococcal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was done in primary care pediatric clinics, between january and may 2007.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MENC-TT/MENC-TT</title>
          <description>Children primovacccinated with two MenC-TT vaccine doses and primed with MenC-TT vaccine</description>
        </group>
        <group group_id="P2">
          <title>MENC-TT/MENC-CRM</title>
          <description>Children primovacccinated with two MenC-TT vaccine doses and primed with MenC-CRM vaccine</description>
        </group>
        <group group_id="P3">
          <title>MENC-CRM/MENC-TT</title>
          <description>Children Primed with three doses of MenC-CRM vaccine and boosted with MenC-TT</description>
        </group>
        <group group_id="P4">
          <title>MENC-CRM/MENC-CRM</title>
          <description>Children primed with 3 doses of MenC-CRM vaccine, and boosted with MenC-CRM vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="107"/>
                <participants group_id="P4" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to withdraw blood</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MENC-CRM/MENC-CRM</title>
          <description>Children primed with 3 doses of MenC-CRM vaccine, and boosted with MenC-CRM vaccine</description>
        </group>
        <group group_id="B2">
          <title>MENC-CRM/MENC-TT</title>
          <description>Children Primed with three doses of MenC-CRM vaccine and boosted with MenC-TT</description>
        </group>
        <group group_id="B3">
          <title>MENC-TT/MENC-CRM</title>
          <description>Children primovacccinated with two MenC-TT vaccine doses and primed with MenC-CRM vaccine</description>
        </group>
        <group group_id="B4">
          <title>MENC-TT/MENC-TT</title>
          <description>Children primovacccinated with two MenC-TT vaccine doses and primed with MenC-TT vaccine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="109"/>
            <count group_id="B3" value="89"/>
            <count group_id="B4" value="87"/>
            <count group_id="B5" value="389"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.37" spread="0.23"/>
                    <measurement group_id="B2" value="1.38" spread="0.13"/>
                    <measurement group_id="B3" value="1.43" spread="0.23"/>
                    <measurement group_id="B4" value="1.46" spread="0.09"/>
                    <measurement group_id="B5" value="1.4" spread=".15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Bactericidal Activity Against MenC</title>
        <time_frame>One month after booster dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MENC-TT/MENC-TT</title>
            <description>Children primovacccinated with two MenC-TT vaccine doses and primed with MenC-TT vaccine</description>
          </group>
          <group group_id="O2">
            <title>MENC-TT/MENC-CRM</title>
            <description>Children primovacccinated with two MenC-TT vaccine doses and primed with MenC-CRM vaccine</description>
          </group>
          <group group_id="O3">
            <title>MENC-CRM/MENC-TT</title>
            <description>Children Primed with three doses of MenC-CRM vaccine and boosted with MenC-TT</description>
          </group>
          <group group_id="O4">
            <title>MENC-CRM/MENC-CRM</title>
            <description>Children primed with 3 doses of MenC-CRM vaccine, and boosted with MenC-CRM vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Activity Against MenC</title>
          <units>GMTs</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6786" lower_limit="5023" upper_limit="9167"/>
                    <measurement group_id="O2" value="6278" lower_limit="5359" upper_limit="7932"/>
                    <measurement group_id="O3" value="2061" lower_limit="1599" upper_limit="2627"/>
                    <measurement group_id="O4" value="1746" lower_limit="1378" upper_limit="2213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Antibody Titers Against Haemophilus Influenzae Type b.</title>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MENC-TT/MENC-TT</title>
            <description>Children primovacccinated with two MenC-TT vaccine doses and primed with MenC-TT vaccine</description>
          </group>
          <group group_id="O2">
            <title>MENC-TT/MENC-CRM</title>
            <description>Children primovacccinated with two MenC-TT vaccine doses and primed with MenC-CRM vaccine</description>
          </group>
          <group group_id="O3">
            <title>MENC-CRM/MENC-TT</title>
            <description>Children Primed with three doses of MenC-CRM vaccine and boosted with MenC-TT</description>
          </group>
          <group group_id="O4">
            <title>MENC-CRM/MENC-CRM</title>
            <description>Children primed with 3 doses of MenC-CRM vaccine, and boosted with MenC-CRM vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Antibody Titers Against Haemophilus Influenzae Type b.</title>
          <units>GMCs</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" lower_limit="17.5" upper_limit="32.4"/>
                    <measurement group_id="O2" value="30.8" lower_limit="23.7" upper_limit="40.1"/>
                    <measurement group_id="O3" value="30.5" lower_limit="23.3" upper_limit="40.0"/>
                    <measurement group_id="O4" value="26.0" lower_limit="19.1" upper_limit="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MENC-TT/MENC-TT</title>
          <description>Children primovacccinated with two MenC-TT vaccine doses and primed with MenC-TT vaccine</description>
        </group>
        <group group_id="E2">
          <title>MENC-TT/MENC-CRM</title>
          <description>Children primovacccinated with two MenC-TT vaccine doses and primed with MenC-CRM vaccine</description>
        </group>
        <group group_id="E3">
          <title>MENC-CRM/MENC-TT</title>
          <description>Children Primed with three doses of MenC-CRM vaccine and boosted with MenC-TT</description>
        </group>
        <group group_id="E4">
          <title>MENC-CRM/MENC-CRM</title>
          <description>Children primed with 3 doses of MenC-CRM vaccine, and boosted with MenC-CRM vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>cutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Leishmaniasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>local reactions: pain, induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>acropustulosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Javier Diez-Domingo</name_or_title>
      <organization>Centro Superior de Investigacion en Salud Publica</organization>
      <phone>+34961925937</phone>
      <email>diez_jav@gva.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

